Abbvi today
- 52-week range
- $ 153.58
▼
$ 218.66
- Dividend yield
- 3.12%
- P/e ratio.
- 87.49
- Value is valuable
- $ 211.45
Abbvie Inc. NYSE: ABBV It is traded near a record high level after the company announced a license agreement with Gubra, a Danish company. The agreement applies to an experimental drug to reduce the weight of the gibra, which is in the study of the phase 1.
ABBVIE paid the Gubri of an advance payment for the right to an experimental drug to reduce weight, GUB014295, which is in the test of 1 phase. ABBVIE took the obligation to pay the GUBR up to 1.9 billion dollars based on certain milestones and sales that are performed.
But the step is higher after this announcement continues the point of view on the ABBV stock, which has grown by more than 19% since the beginning of the year. Mood analysts suggest that the shares still take place for work above.
How the Gubram differs from the existing competition
Entrance to the market loss makes sense for abbvie, given that analysts believe that the market for losing weight can cost $ 130 billion by 2030. Novo nordisk a/s is currently NYSE: NVO With the ground and Eli Lilly and Co. NYSE: Lly With Zepbound the main players. And, like these two drugs, GUB014295 (also known as GUBAMY) is an injected drug.
But it is important to note that with lips it offers a clear difference, which, according to Grab, will be an advantage. Both Overpick and Zepbound are aimed at the GLP-1 hormone. On the contrary, lips acts as an analogue of the amylin hormone of the body.
Amilin was identified as a potential therapeutic target for the treatment of obesity. The hormone gives the brain of patients a sensation of completeness, which helps to suppress appetite, reduce food consumption and delay the emptying of the stomach. Optimism is that lips can provide a longer weight management solution. In the results of a six -week study of Grab 1 in 2024, patients reached 3% of weight loss after one dose.
This is not anyone selling, but who buys
In February, Abbvie Insider is traded on Marketbeat Show three different ABBVIE leaders sold the company’s shares in February. Retail investors often attach too much importance when company insiders sell shares. In this case, each transaction was completed in accordance with the rule 10b5-1.
Rule 10b5-1 is a written agreement between a corporate insider and a broker, which establishes predetermined trading instructions with a predetermined price of shares, the amount and date of the transaction. In each case, these plans were drawn up in November 2024.
This is a good reminder that investors, even corporate insiders, sell shares for various reasons. But usually there is only one reason why they buy. And over the past 12 months, six different members of the Congress bought ABBV shares. And, as investors know, trade in the Congress does not have the same supervision, usually 10B5-1, when it comes to potential insider trade.
Analysts increase their price purposes
Dividend payments ABBVIE
- Dividend profitability
- 3.12%
- Annual dividend
- $ 6.56
- Dividend increases the track record
- 53 years
- Annual growth of dividends 3-year
- 6.04%
- Dividend payment coefficient
- 273.33%
- The next payment of dividends
- Maybe. 15
The history of dividends ABBV
Since the announcement of ABBVIE, the announcement of the ABBVIE promotion has reached a record maximum of more than 216 dollars per share. At the time of writing this article, the shares returned to about $ 212, and some investors are concerned about a heavy twelve -month -old share ratio (P/E), which is 88 times.
However, the ABBVIE P/E forward is only about 17X, which is slightly lower than a ten -year -old average level by 20 times. This suggests that instead of being expensive, ABBV shares can be traded at a discount on its historical average and average indicator of other actions in the biopharmaceutical and medical sector.
It seems that this is a consensus of analysts community. Since the announcement of the transaction with the GUBRA, two analytical companies, Bank of America and Wells Fargo, raised their target prices for ABBV shares to 223 and 240 dollars, respectively. Erste Group Bank modernized the shares before a strong purchase.
Investors who want to take part will want to see if other analysts increase their prospects before Abbvie reports income in April. Even if you feel that the action is too expensive, you can consider the beginning of the position just to collect dividends of the company that currently pay $ 6.56 per promotion per year.
Before considering ABBVIE, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market conquers … And Abbvi was not on the list.
While Abbvie is currently having an average purchase rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Enter your email address, and we will send you the MarketBeat leadership for 5G investments and which 5G shares show the greatest promise.
Get this free report